Parkinnova Therapeutics B.V., a startup based in Amsterdam, has received a €350,000 convertible loan from Innovatiefonds Noord-Holland. Parkinnova is developing a new therapy for Parkinson’s disease, based on an innovative class of PDE inhibitors, that can both alleviate symptoms and potentially slow disease progression. Current treatments are aimed at relieving symptoms, but do not address the underlying disease processes.

New therapy
Parkinnova’s new therapy is designed not only to combat symptoms more effectively, but also to slow disease progression, with the goal of a more sustainable and complete treatment. With the new investment, Parkinnova is working to further develop and optimize a new generation of PDE inhibitor. This includes the optimization of molecular properties and extensive preclinical testing to validate efficacy and safety, which is necessary for further clinical development.

Major expectations
With a targeted, innovative therapy, the disease can not only be better treated, but its impact can also be reduced. This offers patients a more effective and sustainable approach, with fewer side effects and possibly a slowing of disease progression. A step toward a future where Parkinson’s no longer dominates patients’ daily lives.

About Parkinnova Therapeutics
Parkinnova Therapeutics B.V. is a biotech spin-off from the University of Amsterdam, founded by Prof. Dr. Marten P. Smidt and Dr. Lars P. van der Heide.

Dr. Lars van der Heide, CSO and co-founder of Parkinnova Therapeutics says:”We believe this new generation of PDE inhibitors offers a promising and targeted approach to treating Parkinson’s. This funding will allow us to take crucial steps in the development of a new therapy that can have a real impact on patients.”